In a sign of confidence in its ‘Pivot to Growth’ strategy, Teva has raised its sales and profit guidance for 2024 after the second quarter brought a significant turnover increase for its generics business across all global regions, as well as positive developments for its burgeoning biosimilars business in the US.
“Building on Teva’s strong performance in the first half of 2024 and expected developments in the second half of the...







